Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Beam Therapeutics (BEAM – Research Report), ACADIA Pharmaceuticals (ACAD – Research Report) and Recursion Pharmaceuticals (RXRX – Research Report).
Beam Therapeutics (BEAM)
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Beam Therapeutics, with a price target of $75.00. The company’s shares closed last Tuesday at $45.07.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of
Currently, the analyst consensus on Beam Therapeutics is a Moderate Buy with an average price target of $51.90, which is a 30.6% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
ACADIA Pharmaceuticals (ACAD)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Hold rating on ACADIA Pharmaceuticals, with a price target of $33.00. The company’s shares closed last Tuesday at $26.36.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ACADIA Pharmaceuticals with a $35.35 average price target.
Recursion Pharmaceuticals (RXRX)
Needham analyst Gil Blum reiterated a Buy rating on Recursion Pharmaceuticals today and set a price target of $17.00. The company’s shares closed last Tuesday at $15.52, close to its 52-week high of $16.75.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Recursion Pharmaceuticals with a $17.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BEAM:
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
- Beam Therapeutics, Inc. (BEAM) Q4 Earnings Cheat Sheet
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Beam Therapeutics upgraded to Overweight from Neutral at JPMorgan
